Business Wire

ESI Group Won the COVID-19 Prize of “L’Usine Digitale Simulation and AI Awards”

14.10.2020 10:00:00 EEST | Business Wire | Press release

Share

Yesterday, October 13th, ESI Group (Paris:ESI), a world player in Virtual Prototyping software and services for industries , was awarded the COVID-19 prize of the 2020 Simulation and Artificial Intelligence Award by “L’Usine Digitale” for its project aiming to prevent office and plant contamination. The ceremony took place during the 15th annual TERATEC Forum that gathers the best international experts in Simulation, HPC, Big Data and Artificial Intelligence; a flagship event that confirms the importance of these technologies for business competitiveness.

The world has been dealing with COVID-19 for several months now. While normalcy seems like a distant possibility, many people from various industries must go back to work, for the economic health of our society. All companies have been mandated to take great precautions and follow all safety measures needed to control and prevent the virus from spreading. ESI took initiative to validate the precautions using state-of-the-art computer modeling in order to contribute to the health of people at work.

ESI Group decided to study the circulation of the virus in the workplace and investigate different contamination scenarios. The goal: to rely on its historical background in materials physics and the talent of its engineers to help preventing the risk of contamination in workplace whether offices or assembly lines.

The spread of particles was simulated, but also pockets of stagnant air were traced out, especially when modeling bigger and/or poorly ventilated spaces. Based on the cough of a person, neighbor or entrant, the simulation considers the density of water vapor and the theoretical distribution of cough particles.

Three technologies were used:

1. Computational Fluid Dynamics to simulate the behavior of flow and cough particles

2. Virtual reality to visualize the scenario in 3D

3. HPC to speed up simulation rendering times

The results highlighted the importance of identifying dead zones (places with air pockets preventing air circulation) not only to adapt the air conditioning and ventilation within the premises but also to optimize seating arrangements. With these scenarios simulated by ESI’s experts, questions raised by industries can be answered paving the way for a safe return to offices and industrial facilities.

"The pandemic appears to be a long-term scenario, so the adoption of a new standard is inevitable, and we are convinced that these studies will greatly contribute to this. These simulations are already used by industrial players, particularly in Asia, and plenty of questions are finally being addressed, specifically in terms of space optimization, air-conditioning/ventilation and social distancing. This award recognizes the work, ideas and commitment of our teams to adapt our solutions to specific situations and be responsible citizens of a safe society.", commented Anshul Gupta, COO at ESI India Business Operations on behalf of teams spanning across India, UK and Germany who are leading this project.

About ESI

Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its turnover was 146M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris. For further information, go to www.esi-group.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28

Press relation – Shan
Lola Gozlan
lola.gozlan@shan.fr
+33 6 24 76 83 40

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye